Y. Okuma

Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study.

K. Naoki, M. Katagiri, S. Igawa, 2019, Clinical lung cancer.

Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors

K. Naoki, M. Katagiri, S. Igawa, 2020, Investigational New Drugs.

Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations

K. Naoki, M. Katagiri, S. Igawa, 2018, Oncology.

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status

K. Naoki, M. Katagiri, S. Igawa, 2018, Thoracic cancer.

Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status

K. Naoki, M. Katagiri, S. Igawa, 2018, Oncology.

Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases

N. Yamamoto, H. Horinouchi, Y. Goto, 2023, ESMO open.